-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAS-004 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAS-004 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAS-004 in Solid Tumor Drug Details: PAS-004 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAS-004 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAS-004 in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAS-004 in Neurofibromatoses Type I (Von Recklinghausen's...
-
Product Insights
NewSleep Apnea Diagnostic Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Sleep Apnea Diagnostic Systems Pipeline Market Report Overview Sleep Apnea Diagnostic Systems include polysomnography systems (PSG systems) used for the screening of sleep apnea. These include systems and devices used for the diagnosis of sleep apnea. One PSG system includes amplifiers, a hard disk, a monitor, a recorder, a laser printer, electrodes, cables, stands, stimulators, chest and abdomen respiration belts, and sensors. Fixed and portable polysomnography systems are tracked under this category. The Sleep Apnea Diagnostic Systems pipeline market report...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewNeurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2024
Empower your strategies with our Neurofibromatoses Type I (Von Recklinghausen's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy,...
-
Product Insights
NewNeurofibromatoses – Drugs In Development, 2024
Empower your strategies with our Neurofibromatoses – Drugs In Development, 2024 report and make more profitable business decisions. Neurofibromatosis (NF) is a term for a group of genetic disorders that cause benign tumors to grow on nerve tissue. There are three types of NF: NF1, NF2, and schwannomatosis. Each type has different signs and symptoms, such as skin spots, freckles, bumps, hearing loss, vision loss, pain, and bone deformities. NF is caused by mutations in certain genes that regulate nerve cell...
-
Product Insights
NewBipolar Disorder (Manic Depression) – Drugs In Development, 2024
Empower your strategies with our Bipolar Disorder (Manic Depression) – Drugs In Development, 2024 report and make more profitable business decisions. Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person's ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of...
-
Product Insights
NewSchizophrenia – Drugs In Development, 2024
Empower your strategies with our Schizophrenia – Drugs In Development, 2024 report and make more profitable business decisions. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia drugs in development market research report provide comprehensive information on the therapeutics under development for Schizophrenia, complete with...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neurofibromatosis type 1 (NF1) is also called von Recklinghausen's disease. It is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by a mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy, and radiation therapy. The NF1 pipeline market research report provides comprehensive information on the therapeutics under development for NF1,...